以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 基因与生理数据联手预测减肥效果 肥胖已成为全球范围的健康难题，影响着超过6.5亿成年人口。尽管如此，减重干预在不同个体间的效果差异巨大，传统"千人一方"的治疗模 式面临诸多挑战。梅奥诊所团队近日在《Cell Metabolism》期刊发表研究，通过结合基因信息和生理参数，创新开发出预测个体减肥药物反 应的新工具，为实现精准化肥胖治疗带来了全新希望。 机器学习方面，研究采用系统性方法构建饱腹感预测模型。首先通过LASSO回归筛选41个候选基因中的10个关键基因，建立遗传风险评分， 结合身高、体重等生理数据，用支持向量机算法整合分析，并采用Yeo-Johnson变换和SMOTE过采样进行数据预处理，最后用10折交叉验证评 估模型性能。 临床验证环节设计了两项随机对照试验。芬特明-托吡酯组为52周RCT，50名受试者递增剂量治疗，评估3个月和52周体重变化；利拉鲁 ...

时代的全球医疗健康版图重构 2025年，医疗健康行业进入结构性重塑期。技术突破、支付改革与数字化浪潮叠加，推动行业从 规模扩张走向价值创造与精准医疗。 中国市场由医保改革与健康消费升级驱动增长；全球范围内，创新压力与资本约束并存，企业必 须以更清晰的战略聚焦应对不确定性。 GLP-1引发医疗需求结构重塑 生存之战：GLP-1药物将如何重塑医疗健康行业 GLP-1 药物的快速崛起正在重塑全球医疗健康行业。作为被视为"医 学奇迹"的新型治疗手段，GLP-1 显著降低多类慢性疾病的风险，却 同时引发医疗服务提供方的结构性焦虑：未来的临床服务需求将下 降，直接冲击行业盈利模式。 精准靶向治疗加速落地 蓄势待发，放射性药物产业迎来发展新纪元 3 放射性药物正成为继 ADC、GLP-1 之后的全新"黄金赛道"，在肿瘤等重 大疾病的精准诊疗中展现突破性潜力。中国市场虽仍处早期，但在巨大 患者需求推动下具备快速扩容空间。 消费者健康需求结构性升级 1 2 一文读懂2025年消费者健康新趋势 后新冠时代，健康焦虑持续存在，新技术与新产品推动消费者从被动 治疗转向主动、前置的健康管理。在中国市场，医保与支付体系改革 叠加消费升级 ...

美国密歇根州立大学研究团队利用捐赠的人类干细胞，成功开发出全球首个"人源化"心脏类器官，能在 暴露于炎症环境时表现出心房颤动特征。这一突破为研究心律失常提供了前所未有的活体人体组织模 型，有望打破该领域30多年来无新药问世的僵局。这项发表于《细胞·干细胞》的研究，标志着人类在 对抗心律失常的道路上迈出了关键一步。 心房颤动影响全球约6000万人，但由于缺乏准确的人类心脏模型，药物研发长期停滞。近30多年来，没 有新药物被开发用于治疗心房颤动。现有疗法往往针对症状而非潜在机制，因此人们对这种疾病仍然治 疗不力。 2020年起，密歇根州立大学发育与干细胞生物学部艾托·阿吉雷团队利用捐赠的人类干细胞，培育出直 径约数毫米的三维心脏类器官。这些类器官不仅拥有类似真实心脏的腔室结构和血管网络，还能自主节 律性跳动。而且这些类器官的节律性搏动非常强劲，无需显微镜即可观察到。 类器官大小与扁豆相仿，精确度极高，使团队能够以前所未有的方式研究心脏发育、疾病和药物反应。 此次研究的关键进展在于，团队首次在类器官中引入了免疫细胞。博士后研究员科林·奥罗克发现，当 类器官暴露于炎症环境时，会出现类似房颤的心律失常；而使用抗炎药物后 ...

Core Insights - The article discusses a groundbreaking study on cardiovascular disease, highlighting the limitations of existing laboratory models in accurately replicating the complex environment of human arteries [2][5] - The research introduces a novel extrusion-on-demand (EoD) bioprinting technology that creates arterial models with micron-level structural fidelity and customizable macro geometries, enabling better understanding of vascular disease mechanisms and personalized treatment approaches [3][8] Summary by Sections Research Background - Cardiovascular disease is the leading cause of death globally, yet research has been hindered by inadequate laboratory models that fail to replicate the intricate interactions involved in vascular diseases [2] - Current models are either overly simplified (2D) or lack the necessary structural and functional complexity (3D), leading to unresolved mechanisms and ineffective drug trials [2] Technological Innovation - The EoD bioprinting technology developed in this study allows for the construction of arterial models that accurately reflect the microenvironment of vascular diseases, including specific gene/protein expressions that enhance endothelial function and barrier integrity [5][6] - This technology bridges the gap between simplified in vitro systems and the complex in vivo environments, providing a biomimetic platform for disease mechanism analysis and therapy evaluation [5][9] Key Findings - The printed arterial models successfully replicate hallmark processes of vascular diseases, such as endothelial dysfunction, immune cell infiltration, and foam cell formation under physiologically relevant flow and inflammatory conditions [8][9] - The response of these models to drugs mirrors in vivo results, establishing their value for preclinical testing and therapeutic discovery [8] Implications for Future Research - This research not only presents a sophisticated vascular model but also offers a blueprint for engineering complex disease environments, paving the way for decoding vascular disease progression, identifying therapeutic targets, and accelerating precision medicine [9]

Core Insights - Lung cancer is the leading cancer globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. EGFR mutations are present in 40-50% of East Asian patients and 10-20% of Caucasian patients [2] - EGFR tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis and quality of life for patients with EGFR-mutated NSCLC, with third-generation EGFR TKIs now considered the standard first-line treatment for advanced cases [2] - Despite the benefits, EGFR TKIs are associated with cardiovascular adverse events, which can lead to treatment interruptions or discontinuations. However, systematic evaluations of their cardiovascular impacts have been lacking [2][3] Study Overview - A recent study published in The BMJ analyzed cardiovascular risks associated with different generations of EGFR TKIs in EGFR-mutated NSCLC patients. This research marks a significant achievement for the First Affiliated Hospital of Henan University of Medicine [3][4] Key Findings - The study found that both first and third-generation EGFR TKIs, as well as their combinations with anti-angiogenic drugs, are linked to increased cardiovascular adverse events. The risk associated with third-generation EGFR TKIs is significantly higher than that of first-generation [4] - A network meta-analysis included 89 randomized controlled trials with 29,813 participants, revealing that third-generation EGFR TKIs are associated with a 118% increase in cardiac adverse events compared to placebo, while first-generation EGFR TKIs are linked to a 51% increase [6] - Specific third-generation EGFR TKIs, such as Osimertinib and Lazertinib, showed particularly high cardiac toxicity, with risks increasing by 153% and 184%, respectively. Different third-generation EGFR TKIs exhibit varying toxicity profiles, necessitating individualized treatment choices [6] Combination Therapy Risks - The study highlighted a "cumulative effect" of cardiovascular risks when EGFR TKIs are combined with other drugs. The combination of first-generation EGFR TKIs with anti-angiogenic drugs primarily increases vascular adverse reactions, while third-generation EGFR TKIs combined with anti-angiogenic therapies increase both cardiac and vascular adverse reactions [8] Clinical Implications - For patients with pre-existing heart conditions, careful drug selection is crucial. It may be advisable to avoid high-risk third-generation EGFR TKIs or their combination with anti-angiogenic drugs [10] - Enhanced cardiovascular monitoring is recommended for patients requiring potent treatments, especially if high-risk regimens are necessary. Personalized treatment decisions are essential to balance expected efficacy and potential cardiovascular risks [11] Conclusion - This research provides valuable evidence for clinical guidelines regarding the cardiovascular toxicity of EGFR TKIs, emphasizing the need to balance treatment efficacy with cardiovascular risks. Continuous monitoring and assessment of safety for new EGFR TKIs are critical as they are developed and applied [12]

Core Insights - The article discusses the effectiveness of oral semaglutide in managing type 2 diabetes and supporting weight loss, providing more options for weight loss medications [8][10][12]. Study Results - Participants taking oral semaglutide experienced a significant weight loss of 5.8 kg and a notable reduction in HbA1c levels from 8.6% to 7.3% over the study period [10][11]. - The study involved 187 participants with an average age of 58 years, where 54% were male and 88% were white. The average duration of diabetes was 8.7 years, with an initial average weight of 103.1 kg [10][11]. - At the end of the study, 48% of participants had HbA1c levels below 7%, indicating improved glycemic control [11]. Treatment Satisfaction - A high level of treatment satisfaction was reported, with 26.1% and 55.4% of participants finding semaglutide easy or very easy to take, respectively [11]. - By the end of the study, approximately 79% of participants continued with oral semaglutide treatment, with an average dosage of 10.6 mg [11]. Mechanism of Action - The study highlights the use of a small molecule permeation enhancer, SNAC, which aids in the absorption of semaglutide in the stomach, ensuring it achieves the same glycemic effects as injectable forms [12][14]. Market Implications - The introduction of oral semaglutide is seen as a game-changer, particularly for individuals who prefer oral medications over injections due to needle phobia [14][15]. - The focus is on personalized treatment options based on patient and clinician goals, enhancing the overall treatment experience [15].

Core Insights - Colorectal cancer (CRC) is the second most common malignant tumor in China, with 517,100 new cases in 2022, accounting for 10.7% of all cancer cases, and 240,000 deaths, representing 9.3% of all cancer deaths [1][12] - The global colorectal cancer drug market is projected to grow from $16.9 billion in 2019 to $25.4 billion by 2024, indicating significant market potential [1][13] - The Chinese colorectal cancer drug market is expected to reach 24.21 billion yuan by 2024, with an 18.5% year-on-year growth [1][16] - The market is characterized by a competitive landscape with multiple companies across different tiers, including leading firms like Junshi Biosciences and others [1][18] Industry Overview - Colorectal cancer drugs include traditional chemotherapy, targeted therapies, and immunotherapies, which are crucial for extending patient survival [2] - The burden of colorectal cancer in China is significant, with over 80% of patients diagnosed at advanced stages, leading to high treatment demands [1][16] - The market is expected to continue growing, with projections of 37.3 billion yuan by 2027 and nearly 60 billion yuan by 2031 [1][20] Competitive Landscape - The colorectal cancer drug industry features a tiered structure: - First tier: Junshi Biosciences - Second tier: Maibao Pharmaceutical, Hutchison China MediTech - Third tier: JAKS Pharmaceuticals, Jinfang Pharmaceutical [1][18] - Over 10 innovative therapies have been approved globally for colorectal cancer treatment, with more in clinical trials [1][18] Future Trends - The market is expected to see a shift towards precision medicine, with targeted and immunotherapies becoming mainstream [1][22] - Domestic innovative pharmaceutical companies are rapidly emerging, enhancing their product lines through independent research and global collaborations [1][23] - Upgraded patient needs will drive innovations in service models, focusing on unmet clinical demands and improving treatment experiences [1][25]

Core Viewpoint - The article emphasizes the critical role of testosterone in male health, highlighting its influence on various physiological functions and the consequences of its imbalance throughout a man's life [3][4][6]. Group 1: Testosterone's Role in Male Health - Testosterone is essential from embryonic development to aging, influencing male reproductive system formation, muscle growth, and overall health [4][6]. - After the age of 30, testosterone levels decline by 1%-2% annually, leading to significant physiological differences over time [4][6]. - Approximately one-third of men over 40 experience testosterone deficiency, exacerbated by factors like obesity and insulin resistance [6][7]. Group 2: Consequences of Testosterone Imbalance - Low testosterone levels can lead to a range of health issues, including sexual dysfunction, muscle loss, decreased bone density, and increased risk of depression and cognitive decline [7][8]. - Men with low testosterone are 2-3 times more likely to suffer from depression, and the incidence of Alzheimer's disease is significantly higher among this group [7][8]. - Conversely, excessively high testosterone levels can result in serious health problems, including aggression and fertility issues, often linked to external hormone abuse [7][8]. Group 3: Personalized Treatment Approaches - Modern medicine has shifted towards personalized treatment for testosterone imbalance, moving away from one-size-fits-all solutions [8][9]. - Testosterone replacement therapy (TRT) now includes various administration methods, such as long-acting injections and transdermal gels, tailored to individual patient needs [8][9]. - Advances in diagnostic techniques allow for a more comprehensive assessment of testosterone levels, incorporating free testosterone and other biomarkers for better treatment outcomes [9][10]. Group 4: Systemic Effects of Testosterone - Testosterone interacts with multiple organ systems, enhancing insulin sensitivity, reducing the risk of metabolic syndrome, and providing cardiovascular protection [10][11]. - It plays a crucial role in maintaining bone density and has been shown to reduce the risk of vertebral fractures by 2-3 times in those with long-term testosterone deficiency [10][11]. - Recent theories challenge the notion that high testosterone levels promote prostate cancer, suggesting that maintaining testosterone balance is more beneficial than suppression [10][11]. Group 5: Innovations in Testosterone Management - The integration of artificial intelligence in testosterone treatment is revolutionizing clinical practices, enabling more accurate predictions of treatment responses and potential side effects [11][12]. - Ongoing research aims to clarify the long-term effects of TRT on cardiovascular health and its complex relationship with prostate diseases [11][12]. - The understanding of testosterone has evolved from merely regulating sexual characteristics to being recognized as a central player in overall metabolic health [11][12].

Core Insights - The number of chronic pancreatitis patients has been increasing significantly, drawing attention from the medical community. The causes are complex and cannot be attributed to a single factor, with poor dietary habits playing a crucial role. Long-term high-fat, high-protein diets, excessive alcohol consumption, and frequent consumption of spicy foods are potential triggers for chronic pancreatitis. The condition leads to chronic inflammation and loss of pancreatic function, and enteric-coated pancreatic enzyme capsules can alleviate the adverse effects caused by insufficient pancreatic secretion, thus treating chronic pancreatitis. The rising number of patients directly drives the demand for enteric-coated pancreatic enzyme capsules, with the market size in China projected to reach 7.11 billion yuan in 2024, reflecting a year-on-year increase of 13.94% [1][11]. Industry Overview - Enteric-coated pancreatic enzyme capsules are digestive aids primarily composed of a mixture of various enzymes extracted from pig pancreas, including protease, lipase, and amylase. Their main function is to supplement the body's required enzymes to improve digestive issues caused by enzyme deficiency or insufficient secretion. The capsules promote fat digestion, assist protein breakdown, facilitate carbohydrate metabolism, alleviate digestive discomfort, and aid in the absorption of fat-soluble vitamins. Adverse reactions are rare, with occasional occurrences of diarrhea, constipation, stomach discomfort, nausea, and skin reactions [3][9]. Market Dynamics - The market for enteric-coated pancreatic enzyme capsules includes several brands such as "Demeitong," "Dashutong," "Chongming," and "Jiayi." The primary products are produced by companies located in Chongqing, Sichuan, and Anhui, with a high market concentration. The competitive landscape is characterized by a variety of brands available in pharmacies and hospitals, with four companies holding production licenses [15][16]. Demographic Trends - The population aged 65 and above in China has been steadily increasing, with projections indicating growth from 177.67 million in 2019 to 219.69 million in 2024, representing an increase in the proportion of elderly individuals from 12.6% to 15.6% of the total population. This demographic shift, often linked to declining birth rates and increased life expectancy, correlates with a higher incidence of chronic diseases and gastrointestinal issues, thereby increasing the demand for enteric-coated pancreatic enzyme products [7][20]. Competitive Landscape - The competitive landscape of the enteric-coated pancreatic enzyme capsule industry is becoming more diverse, with numerous companies entering the market. The market is fragmented, with no single company dominating. As the market expands, companies with innovative capabilities, market sensitivity, and brand advantages are expected to stand out [21][22]. Future Trends - The demand for enteric-coated pancreatic enzyme capsules is anticipated to continue growing due to the aging population and rising incidence of digestive system diseases. Additionally, the market is expected to see increased competition and a shift towards personalized and differentiated products, as companies invest in research and development to meet the diverse needs of different patient groups [20][23].

Core Viewpoint - The increasing incidence of cancer among the elderly in China poses a significant challenge for health management, necessitating personalized treatment approaches and early screening initiatives to improve outcomes for this demographic [1][2][10]. Group 1: Cancer Incidence and Characteristics - The proportion of new cancer cases among individuals aged 60 and above in China is 60.7% [1]. - Common malignancies in the elderly include lung cancer and digestive system cancers, accounting for approximately 65% of new cases in this age group [2]. - Factors contributing to cancer in older adults include age-related genetic mutations and the accumulation of carcinogenic factors over time [2][4]. Group 2: Treatment Approaches - There is a tendency among elderly patients to seek unverified remedies or to avoid conventional treatments due to misconceptions about the effects of surgery and chemotherapy [4]. - Personalized treatment plans are essential, taking into account the unique health status and treatment preferences of elderly patients [4]. - Both Western medicine, including targeted therapies and immunotherapy, and traditional Chinese medicine (TCM) play important roles in treating elderly cancer patients [6][8]. Group 3: Quality of Life and Supportive Care - Enhancing the quality of life for cancer patients can lead to improved survival rates [5]. - TCM practices, such as herbal remedies and acupuncture, have been shown to alleviate discomfort during chemotherapy and radiotherapy [8][9]. - Hospitals are developing unique TCM formulations to address specific symptoms associated with cancer treatments [9]. Group 4: Prevention and Early Detection - Early screening and diagnosis are critical for effective cancer management in the elderly [10]. - Initiatives are underway in various regions to provide free cancer screenings for older adults, targeting high-risk populations [10]. - Lifestyle modifications, including balanced nutrition and physical activity, are recommended to enhance the overall health and resilience of elderly individuals [10].